Cabergoline

Cabergoline produced by Lucius Pharmaceuticals offers patients a convenient and cost-effective treatment option due to its long-acting effect and lower dosing frequency.

Summary of Key Information for Cabergoline.

Active Ingredient

The main active ingredient is cabergoline, which belongs to the class of ergot derivative dopamine receptor agonists.

Target Population

It is indicated for adult patients with hyperprolactinemia.

Dosage and Administration

The recommended initial dose is 0.25 mg, taken orally twice a week. The dose can be gradually adjusted based on the patient’s response, with a maximum dose of 1 mg twice a week.Reference Article: Dosage and Administration of Cabergoline

Use in Special Populations

Special populations such as pregnant women and patients with liver impairment need dose adjustments or should avoid use after evaluation by a physician.

Overdose

In case of overdose, blood pressure support measures should be taken immediately, and professional medical assistance should be sought promptly.

Storage

The medication should be stored in its original packaging at room temperature (20°C–25°C).

Pharmacokinetics

After oral administration, the drug reaches peak concentration within 2–3 hours. It has a long half-life and is mainly excreted via feces and urine.

FDA，2025.04